TLDR: Pharma’s scarcest input is capable people, so employers increasingly buy transferable capability and teach the regulated domain around it. The career changer’s task is making that transfer legible and low-risk.
Scarcity has turned pharma domain knowledge into something employers now teach
The Swiss life sciences labour market entered 2026 with more open specialist roles than qualified applicants, and that imbalance changed what hiring managers optimise for. Where a pharma CV once served as the price of entry, sustained shortage has pushed employers towards a different calculation: buy the capability that takes years to build, and teach the regulatory grammar that takes months. Understanding that trade is most of what a successful career switch requires, because it tells an outsider exactly which part of their profile to lead with, and which part to treat as a gap they will close on the employer’s time.
Analysts tracking persistent talent shortages across Swiss life sciences report that regulatory, scientific and engineering roles stay open longest, and vacancy duration is what forces the shift. A seat left empty for nine months carries real cost through delayed submissions, stretched colleagues and deferred launches. At some point that cost exceeds the cost of training a capable outsider. Employers respond by loosening the requirement they can most cheaply replace, which is prior sector experience, while holding firm on the ones they cannot replace at all: judgement, delivery discipline and the temperament to work inside a documented system. Scarcity does much of the arguing on the candidate’s behalf.
Domain knowledge in pharma is unusually teachable because so much of it sits codified. Good Manufacturing Practice, Good Clinical Practice and Good Distribution Practice exist as written standards. Deviations, corrective actions and change controls run through defined procedures. Submission dossiers follow a common technical document structure that a competent person can learn from the specification itself. Set that against the tacit skills employers genuinely struggle to source: reading a room during an inspection, holding a launch timeline together across four functions, deciding when incomplete data still supports a decision. Codified knowledge transfers through training. Tacit judgement transfers only through years, which is why employers pay for it wherever they find it.
Employers have also grown structurally more comfortable with this route. The World Economic Forum’s research on reskilling and internal redeployment describes organisations expecting to close a large share of their skill gaps by developing people rather than replacing them, and a company that has built machinery to reskill its own staff can point that machinery at an external hire. Onboarding curricula, mentoring structures, qualification records and training matrices already exist inside regulated firms because inspectors expect to see them. A career changer arriving in 2026 walks into an infrastructure purpose-built to bring people up to a documented standard and prove it happened.
That leaves the outsider with a narrower and far more answerable question than how to get into pharma. The real question is which capability they hold that the industry currently struggles to buy, and which functions inside pharma are structured to accept it. Those functions are identifiable, they hire against published criteria, and they behave differently enough from one another that choosing the wrong one costs a year of applications and a good deal of confidence. A candidate who understands the difference between a regulatory operations team and a clinical operations team before writing a single application letter has already outpaced most of the field competing for the same seats.
Four role families hire for capability and supply the science afterwards
Pharmaceutical companies are frequently imagined as laboratories with an administrative wrapper, and their headcount says otherwise. A mid-size Swiss pharmaceutical employer runs project managers, quality specialists, data engineers, supply planners, medical writers, market access analysts and commercial teams in numbers that dwarf its bench scientists. Most of those functions never touch a pipette. Four of these families open reliably to outsiders, each for its own structural reason, and each rewards a different starting profile, which makes the choice of target function the single highest-leverage decision a career changer makes.
| Role family | What transfers in | Typical entry title | What to learn fast |
|---|---|---|---|
| Regulatory operations and quality | Documentation discipline, audit exposure, process ownership | Regulatory operations associate, QA officer | GxP, change control, dossier structure |
| Clinical operations and project management | Multi-party delivery, vendor and timeline control | Clinical trial administrator, project coordinator | ICH Good Clinical Practice, protocol logic |
| Commercial, market access and brand-tech | Execution inside constrained marketing environments | Omnichannel manager, market access analyst | Promotional codes, payer and pricing logic |
| Data, analytics and engineering | Statistics, pipeline build, systems validation | Data analyst, validation engineer | Data integrity, computerised system validation |
Regulatory operations and quality assurance absorb outsiders most readily because the work rewards habits over pedigree. Someone who has run document control in aerospace, managed an ISO 9001 audit cycle, or owned change management inside a bank already thinks in versions, approvals and traceability. The mechanism is plain: an inspector examines evidence, so the job amounts to producing evidence that survives examination, and that discipline is sector-agnostic. What must be acquired is the vocabulary and the regulatory map — which authority governs which product, what Swissmedic expects of a Swiss marketing authorisation, how an EMA centralised procedure differs from a national one. Employers budget for that learning. They rarely budget for teaching an adult to be meticulous.
Clinical operations rewards a different strength. Running a trial means coordinating investigator sites, contract research organisations, ethics committees, supply chains and data teams across several countries, each with its own approval clock. That is a delivery problem wearing a scientific coat, which is why programme managers from construction, telecoms and enterprise software succeed in it so often. The learning curve sits in protocol literacy and in ICH Good Clinical Practice, both formally examinable. A candidate who describes how they recovered a slipping multi-vendor programme, names the trade-offs they accepted and shows what they documented is already speaking the language of clinical operations without using a single clinical term.
Commercial and data roles open for a third reason: the constraint travels with the candidate. Pharmaceutical marketing operates under promotional codes that forbid much of what other sectors do freely, so the most valuable commercial hires often arrive from other constrained environments — financial services marketing under FINMA supervision, insurance, medical publishing. Brand-tech profiles who have built compliant customer journeys elsewhere adapt quickly because they already treat legal review as part of the creative process rather than an obstacle to it. Analytics and engineering transfer even more directly, though computerised system validation catches newcomers out; a pipeline feeding a regulatory submission must be shown to do what it claims, permanently and reproducibly.
Choosing among these four is a strategic decision rather than an application-volume exercise. Each family carries its own entry title, its own accepted proof and its own ceiling for someone without a science degree, and applying broadly across all four signals indecision rather than range. Once a candidate has picked, the remaining work turns evidentiary. A hiring manager needs to see that the transfer has already happened in miniature, somewhere in the existing record, before funding it at full scale. That evidence exists in most experienced careers; it usually sits buried under job titles that hide it.
A convincing application shows decisions taken under audit, not vocabulary borrowed from a glossary
The most common failure in a pharma career-change application is a fluency mismatch. A candidate reads a primer, seeds the CV with GxP, validation and compliance, and produces a document a regulatory affairs manager dismisses in fifteen seconds, because the borrowed terms sit beside achievements that have nothing to do with them. The repair is to lead with genuine evidence of working under external scrutiny and let terminology follow behind it.
Evidence of scrutiny has a recognisable shape, and the people who hold it rarely realise it counts. A financial controller who has survived an external audit has defended a position with documentation. A food manufacturing supervisor who has owned a HACCP plan has run a hazard analysis carrying legal consequences. An IT lead who prepared a bank for a GDPR or revised Swiss Federal Act on Data Protection assessment has mapped data flows and justified controls to a supervisory authority. Each is structurally identical to what a pharma quality role demands: a claim, the evidence behind it, and a person willing to be examined on both. Written that way, an achievement needs no borrowed vocabulary to land.
The transfer does fail in predictable places, and naming them protects a candidate from a wasted year. Roles requiring a Qualified Person under EU law, along with most senior medical and pharmacovigilance positions, carry statutory qualification requirements that transferable skill alone will never satisfy. Clinical evaluation writing under the Medical Device Regulation expects real scientific literacy. Where the barrier is legal rather than cultural, the honest move is to route around it: enter through an adjacent function, acquire the qualification deliberately, or accept a different ceiling for now. Candidates who push at a statutory boundary spend credibility that a lateral entry would have preserved intact.
Deliberate, visible investment closes the remaining distance. A recognised course in Good Clinical Practice or regulatory affairs, completed before applying rather than promised during an interview, converts stated intention into demonstrated commitment, and it costs a fraction of what most hiring managers assume. Structured business education builds the second half of the case — the commercial reasoning, stakeholder handling and judgement that senior regulated roles run on. The pairing does the persuading: technical study proves the domain can be learned, and business training proves the candidate will be worth promoting once it has been.
An application built this way survives the first screen on its merits, and it earns the interview where the real case gets made. Whether it converts often turns on geography rather than capability, because the Swiss and European markets impose entry conditions unrelated to how good any given candidate is. Permits, languages and the physical location of a company’s regulatory function narrow the reachable list long before a hiring manager reads a word of it. Candidates who map those conditions early stop spending effort on roles that were closed to them from the start.
Permits, language lines and the location of the regulatory function decide which openings are reachable
Two candidates with identical profiles meet completely different markets depending on nationality and residence, and career advice that ignores this wastes people’s time. Switzerland’s labour market access rules, its linguistic geography, and the way multinationals distribute regulatory work across Basel, Zug, Geneva, Dublin and Amsterdam together shape which entry roles a given person can realistically win. Mapping those constraints first turns a long, discouraging search into a short, plausible one.
Permit status sets the outer boundary. Citizens of EU and EFTA states move under the free movement agreement and hold B or C permits with broad access, cross-border commuters into Basel and Geneva work on the G permit, and short assignments run on L. Third-country nationals face quota-limited authorisations an employer must actively justify, which raises the bar a newcomer has to clear: a company will sponsor a genuinely scarce regulatory specialist far more readily than a career changer competing against resident applicants. The consequence is one of sequencing. Candidates without automatic access fare better entering through an employer’s EU entity, or through a scarce specialism, then moving internally once inside the group.
Language works as a second filter, and it varies by canton and by function. Anglophone working environments dominate research, clinical development and global regulatory teams around Basel and Zug, where a career changer with strong English competes on equal terms from day one. Quality and manufacturing roles closer to the site floor usually expect working German or Swiss German, because deviations get discussed with operators rather than in meeting rooms. French-speaking Switzerland runs much of its MedTech and commercial hiring in French. Identifying which combination a target function actually uses, then investing precisely where the gap sits, converts a vague disadvantage into a finite task.
Where the Swiss route stays closed, the surrounding European market frequently opens. The European Medicines Agency’s move to Amsterdam pulled regulatory activity towards the Netherlands, Ireland hosts substantial manufacturing and quality operations, and Germany’s device industry has absorbed the workload created by the Medical Device Regulation and In Vitro Diagnostic Regulation transitions. Those markets hire against comparable criteria with lighter entry conditions for EU nationals, and experience earned in them reads as directly relevant when a Swiss opening appears later. Entering the sector counts for more than entering it in a particular postcode.
Made this way, the switch compounds. Two years inside a regulatory operations team or a clinical programme converts a career changer into an internal candidate, and internal candidates get assessed on delivery rather than on the sector their previous employer occupied. The scarce commodity in 2026 is a person who combines regulated discipline with capability the industry has historically had to import. That description fits a great many outsiders who have yet to recognise themselves in it.
Edward Galle places compliance-literate and brand-tech talent across pharma, MedTech, life sciences and finance in Switzerland, the EU and the United States. Candidates ready to move can submit a CV for spontaneous consideration, review current openings, or build commercial judgement through our Harvard Business Review-backed training programme.
References
- Panda International. Swiss Life Sciences Hiring Trends for 2026. https://www.panda-int.com/en-ch/insights/swiss-life-sciences-hiring-trends-for-2026/
- World Economic Forum. Future of Jobs Report. https://www.weforum.org/publications/the-future-of-jobs-report-2025/
